This move is archived. Current quotes and coverage live on the stock page.
Follow REGN
Regeneron Pharmaceuticals Inc is experiencing a notable uptick in its stock price, reflecting positive market sentiment and strategic developments.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is rising today, with shares climbing 1.45% to close at CA$809.72. The company's advancements in the biotech sector and its strategic collaborations are contributing to this positive momentum.
Investor takeaway: Investors should consider Regeneron's strong market position and ongoing developments in gene editing and rare disease treatments as potential drivers for future growth.
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$100.69B
P/E
21.5x
Div. yield
0.38%
Div. / share
$3.70
52W high
$991.73
52W low
$590.83
1W change
+14.44%
Beta
0.10
Analyst Price Targets
Based on 28 analysts covering REGN · as of Nov 5, 2026
Wall Street analysts forecast REGN stock price to rise 4.9% over the next 12 months.
Consensus
Buy4.18 / 5.00
Avg. Target
C$976.44
+4.9% Upside
Previously C$969.59 on Nov 4, 2026
Current Price
C$930.67
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
48.0%
Annualized
90-Day Vol
37.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$1112.62
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$987.75 | C$837.10 – C$1165.51 |
| 60 trading days | C$1048.33 | C$829.58 – C$1324.76 |
| 90 trading days | C$1112.62 | C$835.34 – C$1481.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Market Cap: CA$82.18 Billion
Regeneron's substantial market capitalization reflects its established presence and investor confidence in its growth potential.
Bull case
Regeneron has a strong lineup of innovative therapies, especially in gene editing, which could significantly boost its revenue. The company's partnership with Intellia Therapeutics on CRISPR-based therapies places it in a favorable position within a rapidly growing market.
Bear case
Despite its strengths, Regeneron faces challenges, such as competition in the biotech industry and possible regulatory hurdles that could affect the development of its pipeline products.
Strategic Collaborations Boost Growth
Regeneron's collaboration with Intellia Therapeutics on CRISPR-based therapies is a key factor in its stock performance. This partnership aims to create innovative treatments for rare genetic diseases, targeting a lucrative market expected to expand significantly over the next decade.
Pipeline of Innovative Therapies
The company's strong pipeline includes therapies for eye conditions, allergic diseases, and cancer, positioning Regeneron as a leader in the biotech industry. As these products move through clinical trials, they could offer substantial revenue opportunities, further boosting investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
